



# Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. *Cancers* 2022, 14, 5461


Rie von Eyben <sup>1</sup>, Daniel S. Kapp <sup>2</sup>, Manuela Andrea Hoffmann <sup>3,4</sup>, Cigdem Soydal <sup>5</sup>, Christian Uprimny <sup>6</sup>, Irene Virgolini <sup>6</sup>, Murat Tuncel <sup>7</sup>, Mathieu Gauthé <sup>8</sup> and Finn E. von Eyben <sup>9,\*</sup>

- <sup>1</sup> Cytel Incorporated, 1050 Winter St, Waltam, MA 02452, USA
- <sup>2</sup> Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA 94305, USA
- <sup>3</sup> Department of Occupational Health & Safety, Federal Ministry of Defense, 53123 Bonn, Germany
  - <sup>4</sup> Department of Nuclear Medicine, University Medical Center, Johannes Gutenberg University in Mainz, 55101 Mainz, Germany
  - <sup>5</sup> Department of Nuclear Medicine, University of Ankara, Ankara 06100, Turkey
  - <sup>6</sup> Department of Nuclear Medicine, University Hospital in Innsbruck, 6020 Innsbruck, Austria
  - <sup>7</sup> Department of Nuclear Medicine, Hacettepe University, Ankara 06230, Turkey
  - <sup>8</sup> Department of Nuclear Medicine, Incept, Institute Holland, 38100 Grenoble, France
- <sup>9</sup> Center of Tobacco Control Research, 5320 Odense, Denmark
- \* Correspondence: finn113edler@mail.tele.dk

### **Error in Figure**

In the original publication [1], there was a mistake in Figure 6. The lower line that shows the control group treatment is ADT + SDaRT + MDT; however, it should only include ADT + MDT. The corrected Figure 6 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

#### **Corrected Figure 6**



#### Received: 13 December 2022 Accepted: 14 December 2022 Published: 7 February 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

## Reference

 von Eyben, R.; Kapp, D.S.; Hoffmann, M.A.; Soydal, C.; Uprimny, C.; Virgolini, I.; Tuncel, M.; Gauthé, M.; von Eyben, F.E. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. *Cancers* 2022, 14, 5461. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: von Eyben, R.; Kapp, D.S.; Hoffmann, M.A.; Soydal, C.; Uprimny, C.; Virgolini, I.; Tuncel, M.; Gauthé, M.; von Eyben, F.E. Correction: Von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. *Cancers* 2022, *14*, 5461. *Cancers* 2023, *15*, 1035. https:// doi.org/10.3390/cancers15041035

*Cancers* **2023**, *15*, 1035. https://doi.org/10.3390/cancers15041035